Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AIM Vaccine Co's Total Liabilities for the quarter that ended in Jun. 2026 was HK$4,081 Mil.
AIM Vaccine Co's quarterly Total Liabilities
increased
from Jun. 2025 (HK$3,982.54 Mil) to Dec. 2025 (HK$3,985.81 Mil) and
increased
from Dec. 2025 (HK$3,985.81 Mil) to Jun. 2026 (HK$4,081.15 Mil).
AIM Vaccine Co's annual Total Liabilities
increased
from Dec. 2023 (HK$3,688.68 Mil) to Dec. 2024 (HK$3,953.82 Mil) and
increased
from Dec. 2024 (HK$3,953.82 Mil) to Dec. 2025 (HK$3,985.81 Mil).
The historical data trend for AIM Vaccine Co's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
AIM Vaccine Co's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of HK$4,081 Mil mean?
AIM Vaccine Co (HKSE:06660) has a Total Liabilities of HK$4,081 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for AIM Vaccine Co and its competitors.
Is AIM Vaccine Co's Total Liabilities too high?
AIM Vaccine Co's current Total Liabilities is HK$4,081 Mil. Overall, AIM Vaccine Co has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM Vaccine Co's Total Liabilities compare to VRTX and REGN?
AIM Vaccine Co's Total Liabilities of HK$4,081 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for AIM Vaccine Co and its competitors. AIM Vaccine Co's current Total Liabilities is HK$4,081 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM Vaccine Co stock overvalued right now?
Based on GuruFocus' analysis, AIM Vaccine Co (HKSE:06660) is currently considered Possible Value Trap. The stock's GF Value™ is HK$4.08, compared to a current price of HK$1.67 — trading 59.1% below its estimated fair value. The current Total Liabilities is HK$4,081 Mil. AIM Vaccine Co's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For AIM Vaccine Co (HKSE:06660), the current Total Liabilities is HK$4,081 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AIM Vaccine Co (HKSE:06660) Overvalued in 2026?
Based on GuruFocus' analysis, AIM Vaccine Co stock appears to be undervalued.
The current stock price of HK$1.67 is trading 59.1% below its estimated GF Value™ of HK$4.08.
GuruFocus considers AIM Vaccine Co to be Possible Value Trap.
Key valuation signals for HKSE:06660:
Total Liabilities: HK$4,081 Mil
GF Value™: HK$4.08 vs. price of HK$1.67 (59.1% below fair value)
No single metric tells the full story. See the HKSE:06660 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AIM Vaccine Co Ltd is a China-based full-chain vaccine company engaged in the research and development, manufacturing, and commercialization of vaccine products. The company's commercialized products include recombinant HBV vaccines, freeze-dried human rabies vaccines, inactivated HAV vaccines, Group A, C, Y, and W135 meningococcal polysaccharide vaccines, bivalent inactivated HFRS vaccines, and mumps vaccines. The company generates the majority of its revenue from the PRC.
61GF Score
Get the complete analysis for HKSE:06660
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06660 has been successfully added to your 
